Pediatric population reference value distributions for cancer biomarkers and covariate-stratified reference intervals in the CALIPER cohort

Clinical Chemistry

Volumn 60, Issue 12, 2014, Pages 1532-1542

  Bevilacqua, Victoria ^a,b   Chan, Man Khun ^a   Chen, Yunqi ^a   Armbruster, David ^c   Schodin, Beth ^c   Adeli, Khosrow ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ABBOTT DIAGNOSTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; PROGASTRIN RELEASING PEPTIDE; PROSTATE SPECIFIC ANTIGEN; SQUAMOUS CELL CARCINOMA ANTIGEN; THYROGLOBULIN ANTIBODY; TUMOR MARKER;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER THERAPY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PARENTAL CONSENT; QUALITY CONTROL; REFERENCE VALUE; BLOOD; CLINICAL CHEMISTRY; DEVICES; LABORATORY AUTOMATION; PRESCHOOL CHILD; SEXUAL DEVELOPMENT; STANDARDS;

ADOLESCENT; ADULT; AUTOMATION, LABORATORY; CHILD; CHILD, PRESCHOOL; CLINICAL CHEMISTRY TESTS; COHORT STUDIES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; REFERENCE VALUES; SEX CHARACTERISTICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84924439698     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2014.229799     Document Type: Article

References (40)

1. Gutierrez A, Martinez-Serra J, Barcelo B, Sampol A, Vinas L, Gonzalez G, et al. Prognostic value of serum CA125 levels in diffuse large B-cell lymphoma: potential role of a new sex- and age-adjusted reference value. Int J Lab Hematol 2010; 32:582-9.
2. Baranzelli MC, Kramar A, Bouffet E, Quintana E, Rubie H, Edan C, Patte C. Prognostic factors in children with localized malignant nonseminomatous germ cell tumors. J Clin Oncol 1999; 17:1212.
3. Pauniaho SL, Tatti O, Lahdenne P, Lindahl H, Pakarinen M, Rintala R, Heikinheimo M. Tumor markers AFP, CA 125, and CA 19-9 in the long-term follow-up of sacrococcygeal teratomas in infancy and childhood. Tumour Biol 2010; 31: 261-5.
4. Li J, Chen H, Mariani A, Chen D, Klatt E, Podratz K, et al. HE4 (WFDC2) promotes tumor growth in endometrial cancer cell lines. Int J Mol Sci 2013; 14:6026-43.
5. Bast RC Jr, Spriggs DR. More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis. Gynecol Oncol 2011; 121:429-30.
6. Wong JR, Harris JK, Rodriguez-Galindo C, Johnson KJ. Incidence of childhood and adolescent melanoma in the United States: 1973-2009. Pediatrics 2013; 131:846-54.
7. Lahdenne P, Pitkanen S, Rajantie J, Kuusela P, Siimes MA, Lanning M, Heikinheimo M. Tumor markers CA 125 and CA 19-9 in cord blood and during infancy: developmental changes and use in pediatric germ cell tumors. Pediatr Res 1995; 38:797-801.
8. Colantonio DA, Kyriakopoulou L, Chan MK, Daly CH, Brinc D, Venner AA, et al. Closing the gaps in pediatric laboratory reference intervals: a caliper database of 40 biochemical markers in a healthy and multiethnic population of children. Clin Chem 2012; 58:854-68.
9. Bailey D, Colantonio D, Kyriakopoulou L, Cohen AH, Chan MK, Armbruster D, Adeli K. Marked biological variance in endocrine and biochemical markers in childhood: establishment of pediatric reference intervals using healthy community children from the CALIPER cohort. Clin Chem 2013; 59:1393-405.
10. Konforte D, Shea JL, Kyriakopoulou L, Colantonio D, Cohen AH, Shaw J, et al. Complex biological pattern of fertility hormones in children and adolescents: a study of healthy children from the caliper cohort and establishment of pediatric reference intervals. Clin Chem 2013; 59:1215-27.
11. Statistics Canada. Ethnic origins, 2006 counts, for Canada, provinces and territories - 20% sample data [Table]. http://www12.statcan.ca/censusrecensement/2006/dp-pd/hlt/97-562/pages/page.cfm?Lang=E&Geo=PR&Code=01&Table=2&Data=Count&StartRec=1&Sort=3&Display=All (Accessed October 2014).
12. Harris EK, Boyd JC. On dividing reference data into subgroups to produce separate reference ranges. Clin Chem 1990; 36:265-70.
13. Filiben JJ The probability plot correlation coefficient test for normality. Technometrics 1975; 17: 111-7.
14. Tukey JW Exploratory data analysis. Boston: Addison-Wesley; 1977.
15. Hubert M, Van derVeeken S. Outlier detection for skewed data. J. Chemometrics 2008; 22:235-46.
16. Horn PS, Pesce AJ. Reference intervals: a user's guide. Washington, DC: AACC Press; 2005.
17. Lahdenne P, Kuusela P, Siimes MA, Ronnholm KA, Salmenpera L, Heikinheimo M. Biphasic reduction and concanavalin a binding properties of serum alpha-fetoprotein in preterm and term infants. J Pediatr 1991; 118:272-6.
18. Adachi N, Aoyagi K, Saito M, Matsuda I, Yamaguchi K. Age-related changes of serum progastrinreleasing peptide levels during childhood. Acta Paediatr Jpn 1997; 39:336-8.
19. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999; 9:67-81
20. Sarandakou A, Protonotariou E, Rizos D. Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci 2007; 44:151-78.
21. Kim MR, Gupta MK, Travers SH, Rogers DG, Van Lente F, Faiman C. Serum prostate specific antigen, sex hormone binding globulin and free androgen index as markers of pubertal development in boys. Clin Endocrinol (Oxf) 1999; 50:203-10.
22. Randell EW, Diamandis EP, Ellis G. Serum prostate-specific antigen measured in children from birth to age 18 years. Clin Chem 1996; 42: 420-3.
23. Ghosh I, Bhattacharjee D, Das AK, Chakrabarti G, Dasgupta A, Dey SK. Diagnostic role of tumour markers CEA, CA15-3, CA19-9 and CA125 in lung cancer. Indian J Clin Biochem 2013; 28:24-9.
24. Taubner K, Schubert G, Pulzer F, Pfaeffle R, Korner A, Dietz A, et al. Serum concentrations of anti-thyroid peroxidase and anti-thyroglobulin antibodies in children and adolescents without apparent thyroid disorders. Clin Biochem 2014; 47:3-7.
25. Pickett AJ, Jones M, Evans C. Causes of discordance between thyroglobulin antibody assays. Ann Clin Biochem 2012; 49:463-7.
26. UK NEQAS annual report 2007: immunology, allergy and immunochemistry. http://www.immqas.co.uk/downloads/UKNEQASAnnualReport2007Version8.pdf (Accessed October 2014).
27. Henry NL, Hayes DF. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist 2006; 11:541-52.
28. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008; 54:e11-79.
29. Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm. Br J Cancer 2011; 104:863-70.
30. Duffy MJ Tumor markers in clinical practice: a review focusing on common solid cancers. Med Princ Pract 2013; 22:4-11.
31. Cheah PL, Liam CK, Yap SF, Looi LM. Squamous cell carcinoma antigen as an adjunct tumour marker in primary carcinoma of the lung. J Clin Pathol 1994; 47:535-7.
32. Molina R, Filella X, Auge JM. ProGRP: a new biomarker for small cell lung cancer. Clin Biochem 2004; 37:505-11.
33. Brinc D, Chan MK, Venner AA, Pasic MD, Colantonio D, Kyriakopolou L, Adeli K. Long-term stability of biochemical markers in pediatric serum specimens stored at-80 degrees C: a CALIPER substudy. Clin Biochem 2012; 45:816-26.
34. Estey MP, Cohen AH, Colantonio DA, Chan MK, Marvasti TB, Randell E, et al. CLSI-based transference of the CALIPER database of pediatric reference intervals from Abbott to Beckman, Ortho, Roche and Siemens clinical chemistry assays: direct validation using reference samples from the CALIPER cohort. Clin Biochem 2013; 46:1197-219.
35. Erden G, Barazi AO, Tezcan G, Yildirimkaya MM. Biological variation and reference change values of CA 19-9, CEA, AFP in serum of healthy individuals. Scand J Clin Lab Invest 2008; 68:212-8.
36. Ringel MD, Nabhan F. Approach to follow-up of the patient with differentiated thyroid cancer and positive anti-thyroglobulin antibodies. J Clin Endocrinol Metab 2013; 98:3104-10.
37. Lahdenne P, Heikinheimo M. Clinical use of tumor markers in childhood malignancies. Ann Med 2002; 34:316-23.
38. Kutluk T, Varan A, Erbas B, Buyukpamukcu M. Serum CA 125 levels in children with nonHodgkin's lymphoma. Pediatr Hematol Oncol 1999; 16:311-9.
39. Yamashita S, Tokuishi K, Moroga T, Yamamoto S, Ohbo K, Miyahara S, et al. Serum level of HE4 is closely associated with pulmonary adenocarcinoma progression. Tumour Biol 2012; 33:2365-70.
40. Torre GC SCC antigen in malignant and nonmalignant squamous lesions. Tumour Biol 1998; 19: 517-26.